Encorium Group, Inc. (ENCO) announced that the company has elected Linda Nardone, Ph.D as Chief Operating Officer and Executive Vice President. Dr. Nardone will report to Kenneth M. Borow, M.D., Encorium’s President and Chief Executive Officer, and will work out of the Company’s corporate headquarters in Wayne, PA.
Dr. Nardone, having more than 20 years of various clinical trial experience, is suited to serve as Encorium’s CEO and Executive Vice President. Dr. Nardone has been employed with such companies as Pharmacia, Inc. (acquired by Pfizer in 2003), Sterling Winthrop, Inc., Immunomedics, Inc., and Elusys Therapeutics, Inc. Most recently, Dr. Nardone served as General Manager for Zila Biotechnology.
Dr. Nardone earned her Ph.D. in physiology from Pennsylvania State University, and holds a B.S. in Science from Fairleigh Dickinson University.
Dr. Borow stated, “Dr Nardone is a highly experienced leader with a track record of success in all aspects of biopharmaceutical development. Her thorough understanding of the integrated nature of clinical operations and regulatory affairs will be particularly valuable to companies as they face sensitive issues regarding financial and personnel resource constraints, the need for a highly focused and timely plan to support regulatory approval, and the achievement of timelines without compromise to the quality of deliverables.”
Dr. Borow concluded, “From the beginning of our search process for the COO position we sought an individual who could contribute significantly to our senior management team while leading our Global Operations and Regulatory Affairs groups. I believe that Dr. Nardone’s unique combination of experience relating to clinical research operations, regulatory and medical affairs, and business development will prove invaluable to Encorium Group in the future.”
Dr. Nardone stated, “I am excited about joining the team at Encorium Group and helping to implement the global operational vision for the company. Our focus will be on continuing to provide our sponsors with quality in clinical research while maintaining highly efficient operations over a wide geographic footprint. In addition, I expect to enhance the value of Encorium’s regulatory and clinical input to its clients throughout the entire product development process – from product concept to post-marketing.”
Let us hear your thoughts below: